• 1
    2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. htm. Accessed February 2012.
  • 2
    Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57: 1134.
  • 3
    Tuttle-Newhall JE, Krishnan SM, Levy MF, McBride V, Orlowski JP, Sung RS. Organ donation and utilization in the United States: 1998-2007. Am J Transplant 2009; 9( pt 2): 879893.
  • 4
    Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, Markmann JF. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004; 239: 8792.
  • 5
    Centers for Medicare & Medicaid Services. Medicare and Medicaid programs; conditions for coverage for organ procurement organizations (OPOs). Final rule. Fed Regist 2006; 71: 3098131054.
  • 6
    Chan EY, Olson LC, Kisthard JA, Perkins JD, Bakthavatsalam R, Halldorson JB, et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl 2008; 14: 604610.
  • 7
    de Vera ME, Lopez-Solis R, Dvorchik I, Campos S, Morris W, Demetris AJ, et al. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 2009; 9: 773781.
  • 8
    Merion RM, Pelletier SJ, Goodrich N, Englesbe MJ, Delmonico FL. Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg 2006; 244: 555562.
  • 9
    Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg 2008; 248: 599607.
  • 10
    Skaro AI, Jay CL, Baker TB, Wang E, Pasricha S, Lyuksemburg V, et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery 2009; 146: 543553.
  • 11
    Jay CL, Lyuksemburg V, Kang R, Preczewski L, Stroupe K, Holl JL, et al. The increased costs of donation after cardiac death liver transplantation: caveat emptor. Ann Surg 2010; 251: 743748.
  • 12
    Axelrod DA, Schnitzler M, Salvalaggio PR, Swindle J, Abecassis MM. The economic impact of the utilization of liver allografts with high donor risk index. Am J Transplant 2007; 7: 990997.
  • 13
    Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783790.
  • 14
    Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419425.
  • 15
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464470.
  • 16
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.; for United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 9196.
  • 17
    Salvalaggio PR, Dzebisashvili N, MacLeod KE, Lentine KL, Gheorghian A, Schnitzler MA, et al. The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 2011; 17: 233242.
  • 18
    Jay CL, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg 2011; 253: 259264.
  • 19
    Jay C, Ladner D, Wang E, Lyuksemburg V, Kang R, Chang Y, et al. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant—an analysis of the national registry. J Hepatol 2011; 55: 808813.
  • 20
    Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med 1982; 73: 889897.
  • 21
    Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, et al.; for Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009; 15: 148162.
  • 22
    Axelrod DA, Gheorghian A, Schnitzler MA, Dzebisashvili N, Salvalaggio PR, Tuttle-Newhall J, et al. The economic implications of broader sharing of liver allografts. Am J Transplant 2011; 11: 798807.
  • 23
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855865.
  • 24
    Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy—a decision analysis. Aliment Pharmacol Ther 2007; 26: 11471161.
  • 25
    Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19: 11591172.
  • 26
    Buchanan P, Dzebisashvili N, Lentine KL, Axelrod DA, Schnitzler MA, Salvalaggio PR. Liver transplantation cost in the Model for End-Stage Liver Disease era: looking beyond the transplant admission. Liver Transpl 2009; 15: 12701277.
  • 27
    Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009; 50: 8999.
  • 28
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. Liver Transpl 2008; 14: 173180.
  • 29
    Ammori JB, Pelletier SJ, Lynch R, Cohn J, Ads Y, Campbell DA, Englesbe MJ. Incremental costs of post-liver transplantation complications. J Am Coll Surg 2008; 206: 8995.
  • 30
    Bryce CL, Angus DC, Switala J, Roberts MS, Tsevat J. Health status versus utilities of patients with end-stage liver disease. Qual Life Res 2004; 13: 773782.
  • 31
    McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008; 28: 582592.
  • 32
    Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 2002; 73: 616622.
  • 33
    Shechter SM, Bryce CL, Alagoz O, Kreke JE, Stahl JE, Schaefer AJ, et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making 2005; 25: 199209.
  • 34
    Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000; 95: 497502.
    Direct Link:
  • 35
    Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, Younossi ZM. Health-related quality of life in patients with chronic hepatitis B. Liver Int 2007; 27: 11191125.
  • 36
    Kim WR, Lindor KD, Malinchoc M, Petz JL, Jorgensen R, Dickson ER. Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. Hepatology 2000; 32: 924929.
  • 37
    Longworth L, Young T, Buxton MJ, Ratcliffe J, Neuberger J, Burroughs A, Bryan S; for CELT Project Team. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003; 9: 12951307.
  • 38
    Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 14641472.
  • 39
    Parikh ND, Skaro AI, Ladner D, Lyuksemburg V, Cahan JG, Daud A, et al. Clinical Outcomes and Quality of Life in Recipients of Livers Donated after Cardiac Death. Hepatology 2011; 54: 168.
  • 40
    Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009.
  • 41
    Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147154.
  • 42
    Hornberger JC. The hemodialysis prescription and cost effectiveness. Renal Physicians Association Working Committee on Clinical Guidelines. J Am Soc Nephrol 1993; 4: 10211027.
  • 43
    Tousignant P, Guttmann RD, Hollomby DJ. Transplantation and home hemodialysis: their cost-effectiveness. J Chronic Dis 1985; 38: 589601.
  • 44
    Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003; 75: 16591663.
  • 45
    Maheshwari A, Maley W, Li Z, Thuluvath PJ. Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl 2007; 13: 16451653.
  • 46
    Skaro AI, Jay CL, Ladner D, Abecassis MM. Trends in donation after cardiac death and donation after brain death—reading between the lines. Am J Transplant 2010; 10: 23902391.
  • 47
    Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307313.
  • 48
    Scientific Registry of Transplant Recipients. Program and OPO specific reports. Published October 2009. Accessed February 2012.
  • 49
    Tao R, Ruppert K, Cruz RJJr, Malik SM, Shaikh O, Ahmad J, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl 2010; 16: 12881295.
  • 50
    Taner CB, Bulatao IG, Keaveny AP, Willingham DL, Pungpapong S, Perry DK, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl 2011; 17: 641649.
  • 51
    Lyuksemburg V, Wang E, Jay C, Chang Y, Ladner D, Caicedo JC, et al. The graft failure from hepatitis C virus recurrence—does graft type matter? Hepatology 2011; 52: 396.
  • 52
    Lyuksemburg V, Wang E, Jay C, Chang Y, Ladner D, Caicedo JC, et al. The impact of donation after cardiac death livers on hepatitis C virus recurrence following liver transplantation. Hepatology 2011; 52: 321.
  • 53
    Klein AS, Messersmith EE, Ratner LE, Kochik R, Baliga PK, Ojo AO. Organ donation and utilization in the United States, 1999-2008. Am J Transplant 2010; 10( pt 2): 973986.
  • 54
    Skaro AI, Wang E, Lyuksemburg V, Abecassis M. Donation after cardiac death liver transplantation: time for policy to catch up with practice. Liver Transpl 2012; 18: 58.
  • 55
    Taner CB, Bulatao IG, Willingham DL, Perry DK, Sibulesky L, Pungpapong S, et al. Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors. Liver Transpl 2012; 18: 100111.
  • 56
    Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, et al.; for A2ALL Study Group. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL consortium. Ann Surg 2005; 242: 314323.
  • 57
    UNOS/OPTN (2008). Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA.